文献速递乳腺癌支持与姑息治疗

骨质疏松治疗与绝经后ER+乳腺癌10年结局

Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
PubMed 文献 · Eur J Cancer · 2018-07-20

该前瞻性纵向队列纳入450例接受芳香化酶抑制剂治疗的绝经后ER+乳腺癌患者,中位随访10.3±3.0年。双膦酸盐治疗与复发风险降低(HR=0.51, P=0.03)和死亡风险降低(HR=0.46, P=0.01)显著相关;维生素D缺乏与死亡风险增加显著相关(HR=1.85, P=0.04)。

要点

  • 双膦酸盐治疗与复发风险降低约50%显著相关(HR=0.51, P=0.03)。
  • 维生素D缺乏与死亡风险增加显著相关(HR=1.85, P=0.04)。

核心结论

  • 骨质疏松治疗(包括维生素D和双膦酸盐)与接受芳香化酶抑制剂治疗的ER+乳腺癌患者复发和死亡风险降低约50%相关。

研究设计与样本

  • 前瞻性纵向队列研究,纳入450例接受芳香化酶抑制剂治疗的绝经后局部ER+乳腺癌患者。
  • 分析肿瘤特征、芳香化酶抑制剂治疗开始时的骨骼状态及10年癌症结局,采用Cox模型。

主要发现

  • 30.7%有骨折史,16.9%的T值≤-2.5,11.3%存在维生素D缺乏。
  • 35.3%因骨质疏松接受双膦酸盐治疗,平均疗程5±1.7年。
  • 肿瘤大小(HR=1.32, P≤0.01)和受累淋巴结数量(HR=1.07, P=0.03)与复发显著相关。
  • 癌症诊断年龄(HR=1.07, P≤0.01)和维生素D缺乏(HR=1.85, P=0.04)与死亡风险增加显著相关。

关键数值与推荐

  • 双膦酸盐治疗与复发风险降低显著相关(HR=0.51, P=0.03)。
  • 双膦酸盐治疗与死亡风险降低显著相关(HR=0.46, P=0.01)。
  • 维生素D缺乏与死亡风险增加显著相关(HR=1.85, P=0.04)。
  • 肿瘤大小与复发显著相关(HR=1.32, P≤0.01)。
  • 受累淋巴结数量与复发显著相关(HR=1.07, P=0.03)。

临床怎么用

  • 对接受芳香化酶抑制剂治疗的绝经后ER+乳腺癌患者,评估骨骼健康并管理骨质疏松可能有助于改善长期结局。
  • 双膦酸盐和维生素D补充或可作为改善此类患者预后的辅助措施,但需结合个体情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risk factors for breast cancer relapse are well-known, such as large tumour size or lymph node involvement. The aim of our study was to analyse the influence of bone mineral density, fractures and bisphosphonate or vitamin D prescription on 10 years' breast cancer outcome. PATIENTS AND METHODS: This is a longitudinal and prospective cohort of 450 postmenopausal women with local oestrogen receptor (ER)+ breast cancer. For every patient, we analysed tumour characteristics, bone status at the beginning of aromatase inhibitor treatment and 10 years' cancer outcome with Cox model. RESULTS: Mean follow-up was 10.3 ± 3.0 years. Seventy nine women died, and 75 had a relapse; 30.7% had a history of fracture, 16.9% had a T-score ≤ -2.5 and 11.3% had vitamin D deficiency. Bisphosphonates were prescribed to 35.3% women for osteoporosis for a mean duration of 5 ± 1.7 years. Tumour size (hazard ratio [HR] = 1.32, P ≤ 0.01) and the number of lymph nodes involved (HR = 1.07, P = 0.03) were significantly associated with relapse. Bisphosphonate treatment was significantly associated with a decreased risk of relapse (HR = 0.51, P = 0.03). Age at cancer diagnosis (HR = 1.07, P ≤ 0.01) and vitamin D deficiency (HR = 1.85, P = 0.04) were significantly associated with an increased risk of death, whereas bisphosphonate treatment was associated with a decreased risk of death (HR = 0.46, P = 0.01). CONCLUSION: Osteoporosis treatment, including vitamin D and bisphosphonates, is associated with a 50% reduction of relapse and death in women treated with aromatase inhibitors for ER+ breast cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bouvard B, Chatelais J, Soulié P, et al. Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors. Eur J Cancer. 2018. PMID: 30036740. doi:10.1016/j.ejca.2018.06.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。